ARRDC3 and neoplasm: The tumor inhibition properties of ARRDC3 are presumably facilitated by linking target substrates such as β-adrenergic receptor and integrin β4 to E3 ligase, in which these target substrates become ubiquintinated and degraded by the proteasome [91].